Supplemental Figure 13 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer

Read full text Summarise with VIRAT
Authors: Sarah K. Herzog, Jessica H. Stevens, Guowei gu, Sandra L. Grimm, Kloma T Cardoza, Autumn G.M. Hawkins, Hangqing Lin, Daniela Ramos, Amanda R. Beyer, David G. Edwards, Derek J. Dustin, Harry J. Yang
+7 more Nicole Liang, Ashfia Fatima Khan, Tasneem Bawa-Khalfe, Daniel James McGrail, Shiaw‐Yih Lin, Cristian Coarfa, Suzanne A.W. Fuqua
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Fulv plus Olap treatment increases DNA damage in ESR1m Representative images of immunofluorescent staining of pH2AX foci in WT, Y537S and Y537C after cells were cultured in charcoal stripped medium for 48 hours, followed by treatment with 10 nM Fulvestrant, 5 µM Olaparib, or combination treatment.

Fields of Study & Subjects

PARP inhibition in cancer therapy Advanced Breast Cancer Therapies Estrogen and related hormone effects

Publication details

Publication date
2 April 2026
Language
EN